Phenytoin absorption in patients with ileojejunal bypass

Area of Science:

• Pharmacokinetics
• Gastroenterology
• Drug Metabolism

Background:

• Ileojujenal bypass surgery alters gastrointestinal anatomy.
• Altered anatomy may impact drug absorption and elimination.
• Phenytoin is a commonly prescribed antiepileptic drug.

Purpose of the Study:

• To investigate the pharmacokinetic profile of phenytoin in patients with ileojejunal bypass.
• To compare phenytoin absorption and elimination between patients with and without ileojejunal bypass.
• To determine the clinical implications for phenytoin dosing in this patient population.

Main Methods:

• Oral administration of a 200 mg phenytoin dose.
• Plasma drug concentrations measured over time.
• Area Under the Curve (AUC) and elimination half-life calculated.
• Comparison between ileojejunal bypass patients (n=7) and control subjects (n=9).

Main Results:

• Phenytoin absorption was significantly decreased in the ileojejunal bypass group (P < 0.005).
• The elimination half-life of phenytoin was shorter in the bypass group (15.1 h) compared to controls (17.8 h, P < 0.05).
• Reduced bioavailability suggests potential malabsorption of other poorly soluble drugs.

Conclusions:

• Patients with ileojejunal bypass require higher oral phenytoin doses for therapeutic efficacy.
• Malabsorption of other drugs is probable, necessitating alternative administration routes.
• Parenteral therapy may be essential to ensure adequate drug bioavailability in this cohort.